{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:56:52Z","timestamp":1777503412269,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12072-021-10148-z","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T16:04:26Z","timestamp":1619539466000},"page":"310-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir"],"prefix":"10.1007","volume":"15","author":[{"given":"Pao-Yuan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry Yueh-Hsia","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Chin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Lin","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hao","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwong-Ming","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"King-Wah","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-1967","authenticated-orcid":false,"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"issue":"12","key":"10148_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212\u20139.","journal-title":"Vaccine"},{"key":"10148_CR2","doi-asserted-by":"crossref","unstructured":"Mortality GBD, Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459\u20131544.","DOI":"10.1016\/S0140-6736(16)31012-1"},{"issue":"1","key":"10148_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"issue":"8","key":"10148_CR4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1742-1241.2008.01817.x","volume":"62","author":"A Pozniak","year":"2008","unstructured":"Pozniak A. Tenofovir: what have over 1 million years of patient experience taught us? Int J Clin Pract. 2008;62(8):1285\u201393.","journal-title":"Int J Clin Pract"},{"issue":"5 Suppl","key":"10148_CR5","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S185-195.","journal-title":"Hepatology"},{"issue":"2","key":"10148_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"JE Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191\u2013201.","journal-title":"JAMA"},{"issue":"8","key":"10148_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1086\/656417","volume":"51","author":"HJ Stellbrink","year":"2010","unstructured":"Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963\u201372.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10148_CR8","doi-asserted-by":"publisher","first-page":"e99645","DOI":"10.1371\/journal.pone.0099645","volume":"9","author":"LI Chen","year":"2014","unstructured":"Chen LI, Guh JY, Wu KD, et al. Modification of diet in renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI) equations for Taiwanese adults. PLoS One. 2014;9(6):e99645.","journal-title":"PLoS One"},{"key":"10148_CR9","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1\u2013129."},{"issue":"3","key":"10148_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jocd.2015.06.005","volume":"18","author":"SB Broy","year":"2015","unstructured":"Broy SB, Cauley JA, Lewiecki ME, Schousboe JT, Shepherd JA, Leslie WD. Fracture risk prediction by Non-BMD DXA measures: the 2015 ISCD official positions Part 1: Hip geometry. J Clin Densitom. 2015;18(3):287\u2013308.","journal-title":"J Clin Densitom"},{"issue":"6","key":"10148_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/QAD.0b013e3283262a64","volume":"23","author":"P Labarga","year":"2009","unstructured":"Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689\u201396.","journal-title":"AIDS"},{"issue":"5","key":"10148_CR12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10067-014-2627-x","volume":"35","author":"L Mateo","year":"2016","unstructured":"Mateo L, Holgado S, Marinoso ML, et al. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol. 2016;35(5):1271\u20139.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10148_CR13","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.clinre.2015.01.007","volume":"39","author":"S Harkisoen","year":"2015","unstructured":"Harkisoen S, Arends JE, Hoepelman AI, van Erpecum KJ. Renal proximal tubular dysfunction due to tenofovir in a patient with chronic hepatitis B monoinfection. Clin Res Hepatol Gastroenterol. 2015;39(5):e67-69.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"10148_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/apt.13036","volume":"41","author":"S Koklu","year":"2015","unstructured":"Koklu S, Gulsen MT, Tuna Y, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther. 2015;41(3):310\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10148_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","volume":"57","author":"AM Hall","year":"2011","unstructured":"Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773\u201380.","journal-title":"Am J Kidney Dis"},{"key":"10148_CR16","first-page":"354908","volume":"2011","author":"B Fernandez-Fernandez","year":"2011","unstructured":"Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.","journal-title":"AIDS Res Treat"},{"key":"10148_CR17","first-page":"S296","volume":"54","author":"P Marcellin","year":"2011","unstructured":"Marcellin P, Heathcote EJ, Berg T, et al. 739 Effects of tenofovir disoproxil fumarate on renal function in chronic HBV patients in three global randomized studies. J Hepatol. 2011;54:S296\u20137.","journal-title":"J Hepatol"},{"key":"10148_CR18","doi-asserted-by":"publisher","first-page":"S301","DOI":"10.1016\/S0168-8278(13)60746-1","volume":"58","author":"S Fung","year":"2013","unstructured":"Fung S, Kwan P, Horban A, et al. 744 Tenofovir DF (TDF) is safe and well tolerated in chronic hepatitis B (CHB) patients with pre-existing mild renal impairment. J Hepatol. 2013;58:S301\u20132.","journal-title":"J Hepatol"},{"issue":"1","key":"10148_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1759720X16671927","volume":"9","author":"E Biver","year":"2017","unstructured":"Biver E, Calmy A, Rizzoli R. Bone health in HIV and hepatitis B or C infections. Ther Adv Musculoskelet Dis. 2017;9(1):22\u201334.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10148_CR20","doi-asserted-by":"publisher","first-page":"95 e91","DOI":"10.1016\/j.cmi.2015.05.035","volume":"22","author":"MC Tsai","year":"2016","unstructured":"Tsai MC, Chen CH, Tseng PL, et al. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016;22(1):95 e91-95 e97.","journal-title":"Clin Microbiol Infect."},{"issue":"3","key":"10148_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s10620-017-4448-7","volume":"62","author":"M Riveiro-Barciela","year":"2017","unstructured":"Riveiro-Barciela M, Tabernero D, Calleja JL, et al. Effectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients: validation of the page-B score to predict hepatocellular carcinoma. Dig Dis Sci. 2017;62(3):784\u201393.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10148_CR22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/jac\/dku502","volume":"70","author":"P Maggi","year":"2015","unstructured":"Maggi P, Montinaro V, Leone A, et al. Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. J Antimicrob Chemother. 2015;70(4):1150\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10148_CR23","first-page":"512","volume":"107","author":"P Magalhaes-Costa","year":"2015","unstructured":"Magalhaes-Costa P, Matos L, Barreiro P, Chagas C. Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir. Rev Esp Enferm Dig. 2015;107(8):512\u20134.","journal-title":"Rev Esp Enferm Dig"},{"issue":"6","key":"10148_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4166\/kjg.2016.68.6.317","volume":"68","author":"D Kim","year":"2016","unstructured":"Kim D, Lee J, Kim DH, et al. A case of tenofovir-associated fanconi syndrome in patient with chronic hepatitis B. Korean J Gastroenterol. 2016;68(6):317\u201320.","journal-title":"Korean J Gastroenterol"},{"issue":"9","key":"10148_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/MCG.0000000000000569","volume":"50","author":"S Rodriguez-Novoa","year":"2016","unstructured":"Rodriguez-Novoa S, Garcia-Samaniego J, Prieto M, et al. Altered underlying renal tubular function in patients with chronic hepatitis B receiving nucleos(t)ide analogs in a real-world setting: The MENTE Study. J Clin Gastroenterol. 2016;50(9):779\u201389.","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10148_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s10620-014-3363-4","volume":"60","author":"C Tien","year":"2015","unstructured":"Tien C, Xu JJ, Chan LS, et al. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci. 2015;60(2):566\u201372.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10148_CR27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/hep.27894","volume":"62","author":"GL Wong","year":"2015","unstructured":"Wong GL, Tse YK, Wong VW, Yip TC, Tsoi KK, Chan HL. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology. 2015;62(3):684\u201393.","journal-title":"Hepatology"},{"issue":"10","key":"10148_CR28","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108\u201312.","journal-title":"Arch Intern Med"},{"issue":"3","key":"10148_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10148_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/infdis\/jiu471","volume":"211","author":"US Gill","year":"2015","unstructured":"Gill US, Zissimopoulos A, Al-Shamma S, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015;211(3):374\u201382.","journal-title":"J Infect Dis"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10148-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10148-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10148-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T15:39:27Z","timestamp":1671982767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10148-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10148"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10148-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"27 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors have any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the institutional review board and the Ethics Committee of Chang Gung Memorial Hospital (IRB No: 201900928B0).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The Ethics Committee waived the requirement for informed consent for this study, and all the data were analyzed anonymously.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}